NDAORALTABLET
Approved
Jun 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
DELTASONE (prednisone) by Pfizer is clinical pharmacology naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. First approved in 1955.
Drug data last refreshed 2m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DELTASONE (prednisone) is a synthetic glucocorticoid oral tablet approved in 1955 for anti-inflammatory and immunosuppressive effects across multiple organ systems. It is used as replacement therapy in adrenocortical deficiency and for potent anti-inflammatory treatment in diverse disorders. The drug works by modifying immune responses and producing profound metabolic effects.
LOE Approaching
As a legacy oral corticosteroid approaching LOE with 30% competitive pressure, commercial teams face declining revenue opportunities and potential portfolio consolidation.
Mechanism of Action
CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Started May 2026
30 enrolled
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeT Acute Lymphoblastic Leukemia
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Started Dec 2025
18 enrolled
B-Cell Non-Hodgkin LymphomaBurkitt LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+6 more
Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations
Started Oct 2025
0Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Deleterious HRR Gene MutationBRCA1 Gene Mutation+7 more
Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer
Started Apr 2025
0Prostate CancerCastrate Resistant Prostate CancerHomologous Recombination Deficiency
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Started Apr 2025
594 enrolled
Lymphoma, Large B-Cell, Diffuse
Worked on DELTASONE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.